Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04402086 · ClinicalTrials.gov registry record
Rheumatology Patient Registry and Biorepository
A clinical trial of Systemic Lupus Erythematosus and Psoriatic Arthritis, sponsored by Yale University.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT04402086: Recruiting study of Systemic Lupus Erythematosus and Psoriatic Arthritis, sponsored by Yale University.
NCT04402086 is a study of Systemic Lupus Erythematosus and Psoriatic Arthritis that is actively recruiting participants, run by Yale University. The registered enrollment target is 5,000 participants, above the 330-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (1415% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04402086, a study of Systemic Lupus Erythematosus and Psoriatic Arthritis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
Primary Outcome
Evaluate clinical data and biospecimens to correlate outcomes and biomarkers of rheumatic diseases.
Conditions Studied
Study Locations (1)
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2030-06-01 |
What NCT04402086 shows while recruiting
NCT04402086 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 330-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (1415% higher).
The record links to 10 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 0 interventions.
NCT04402086 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04402086 about?
NCT04402086 is a clinical study titled "Rheumatology Patient Registry and Biorepository". To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
What is the current status of trial NCT04402086?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2020-08-04. Estimated completion is 2030-06-01.
What conditions does trial NCT04402086 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Psoriatic Arthritis, Dermatomyositis, Ankylosing Spondylitis, Rheumatic Diseases.
Who is sponsoring clinical trial NCT04402086?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04402086 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04402086's enrollment target sits among peer trials
5,000 1st of 99 the highest of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
RECRUITING
-
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI